Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Ironwood Pharmaceuticals stock
Learn how to easily invest in Ironwood Pharmaceuticals stock.
Ironwood Pharmaceuticals Inc is a drug manufacturers-specialty & generic business based in the US. Ironwood Pharmaceuticals shares (IRWD) are listed on the NASDAQ and all prices are listed in US Dollars. Ironwood Pharmaceuticals employs 232 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Ironwood Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – IRWD – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
What's in this guide?
- IRWD shares summary
- Compare share dealing platforms
- Is IRWD stock a buy or sell?
- Stock performance over time
- Are IRWD shares over-valued?
- Ironwood Pharmaceuticals's financials
- How volatile are IRWD shares?
- Does Ironwood Pharmaceuticals pay a dividend?
- Have IRWD shares ever split?
- Other common questions
Ironwood Pharmaceuticals stock price (NASDAQ: IRWD)Use our graph to track the performance of IRWD stocks over time.
Ironwood Pharmaceuticals shares at a glance
|Latest market close||$11.14|
|52-week range||$8.78 - $14.27|
|50-day moving average||$11.53|
|200-day moving average||$12.20|
|Wall St. target price||$14.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$3.25|
Buy Ironwood Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Ironwood Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Ironwood Pharmaceuticals price performance over time
|1 week (2022-01-19)||-0.45%|
|1 month (2021-12-23)||-6.15%|
|3 months (2021-10-26)||-12.49%|
|6 months (2021-07-26)||-14.77%|
|1 year (2021-01-26)||9.32%|
|2 years (2020-01-24)||-9.94%|
|3 years (2019-01-25)||12.8423|
|5 years (2017-01-26)||13.9416|
Is Ironwood Pharmaceuticals stock undervalued or overvalued?
Valuing Ironwood Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Ironwood Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Ironwood Pharmaceuticals's P/E ratio
Ironwood Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Ironwood Pharmaceuticals shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Ironwood Pharmaceuticals's EBITDA
Ironwood Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $241.9 million.
The EBITDA is a measure of a Ironwood Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
Ironwood Pharmaceuticals financials
|Revenue TTM||$413.3 million|
|Operating margin TTM||58.45%|
|Gross profit TTM||$298.3 million|
|Return on assets TTM||19.21%|
|Return on equity TTM||18.1%|
|Market capitalisation||$1.8 billion|
TTM: trailing 12 months
Ironwood Pharmaceuticals share dividends
We're not expecting Ironwood Pharmaceuticals to pay a dividend over the next 12 months.
Have Ironwood Pharmaceuticals's shares ever split?
Ironwood Pharmaceuticals's shares were split on a 1194:1000 basis on 1 April 2019. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1194 shares. This wouldn't directly have changed the overall worth of your Ironwood Pharmaceuticals shares – just the quantity. However, indirectly, the new 16.2% lower share price could have impacted the market appetite for Ironwood Pharmaceuticals shares which in turn could have impacted Ironwood Pharmaceuticals's share price.
Ironwood Pharmaceuticals share price volatility
Over the last 12 months, Ironwood Pharmaceuticals's shares have ranged in value from as little as $8.7819 up to $14.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ironwood Pharmaceuticals's is 1.2078. This would suggest that Ironwood Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Ironwood Pharmaceuticals overview
Ironwood Pharmaceuticals, Inc. , a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc. , AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
Ironwood Pharmaceuticals in the news
What to watch today: Wall Street to open lower after Nasdaq's worst week since March 2020
Stocks making the biggest moves in the premarket: Kohl's, Snap, Peloton and more
Earnings playbook: A complete guide to this week's reports, including the first of tech
Frequently asked questionsWhat percentage of Ironwood Pharmaceuticals is owned by insiders or institutions?
Currently 1.379% of Ironwood Pharmaceuticals shares are held by insiders and 112.34% by institutions. How many people work for Ironwood Pharmaceuticals?
Latest data suggests 232 work at Ironwood Pharmaceuticals. When does the fiscal year end for Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals's fiscal year ends in December. Where is Ironwood Pharmaceuticals based?
Ironwood Pharmaceuticals's address is: 100 Summer Street, Boston, MA, United States, 02110 What is Ironwood Pharmaceuticals's ISIN number?
Ironwood Pharmaceuticals's international securities identification number is: US46333X1081 What is Ironwood Pharmaceuticals's CUSIP number?
Ironwood Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 46333X108
More guides on Finder
Today’s top U.S. stocks: Mechel Pao ADRs (MTL ↑8.1%), Sibanye-Stillwater Limited (SBSW ↑7.4%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
How to order free at-home COVID tests today — but note, there’s a wait
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
Today’s top U.S. stocks: Las Vegas Sands (LVS ↑15.3%), Wynn Resorts Limited (WYNN ↑9.1%)
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Ask an Expert